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Mesenchymal stromal cells (MSC) have gained immense attraction in regenerative 
medicine, tissue engineering, and immunotherapy. This is based on their differentiation 
potential and the supply of pro-regenerative and immunomodulatory signals. MSC can 
be isolated from a multitude of tissue sources, but mainly bone marrow, adipose tissue, 
and birth-associated tissues (e.g., umbilical cord, cord blood, placenta) appear to be rel-
evant for clinical translation in immune-mediated disorders. However, only a few studies 
directly compared the immunomodulatory potency of MSC from different tissue sources. 
This review compiles the current literature regarding the similarities and differences 
between these three sources for MSCs with a special focus on their immunomodulatory 
effects on T-lymphocyte subsets and monocytes, macrophages, and dendritic cells.
Keywords: mesenchymal stromal cells, immunomodulation, T cells, regulatory T cells, macrophages, bone 
marrow, adipose tissue, umbilical cord
inTRODUCTiOn
Human mesenchymal stromal cells (MSC) have been an attractive target for translational research in 
a wide range of therapeutic applications due to their paracrine effects, multi-lineage differentiation 
potential and, most importantly, their immunomodulatory properties (1, 2). Bone marrow was the 
first established source of these cells (3). Since then it has been the primary and therefore most 
investigated population. Over the last few years, several other sources for MSC have been identified 
(4, 5). In our view, after bone marrow-derived MSCs (hereafter referred to as BM-MSC), adipose 
tissue-derived MSCs (hereafter referred to as AT-MSC), and birth-associated MSCs (from umbilical 
cord blood, cord tissue, and placenta, referred to as UCB-MSC, UC-MSC, and PL-MSC, respectively) 
(6) are most commonly used as sources of human MSCs in a clinical setting. These may be favored 
due to different advantages: greater yields of MSCs than BM, higher proliferative potential, and no 
ethical restrictions (5–10). It has to be noted that birth-associated tissue is not one single source of 
MSCs but rather a comprising name for several subpopulations, namely amnion, umbilical cord, 
cord blood, and placenta. Most of them can be categorized further into even more subpopulations.
Abbreviations: AT, adipose tissue; BM, bone marrow; CTL, cytotoxic T lymphocytes; DC, dendritic cells; MLR, mixed lym-
phocyte reaction; MSC, mesenchymal stromal cells; PBMC, peripheral blood mononuclear cells; PL, placenta; Treg, regulatory 
T cells; UC, umbilical cord; UCB, umbilical cord blood; WJ, Wharton’s jelly.
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Mesenchymal stromal cells from different sources are similar 
in a range of phenotypic and functional features (5). There are, 
however, subtle differences, which may result from the micro-
environmental niche, the local function (stromal support of 
hematopoiesis in the BM and immune homeostasis by AT), and 
the ontogenetic age (birth-associated versus adult) (5, 7, 11) or 
induced by the isolation and culture procedure. CD106 is one 
example, as it is significantly reduced on AT-MSCs compared to 
other MSCs (5, 12, 13). CD34, on the other hand, appears on 
AT-MSCs in situ and early in culture but on no other MSCs (14, 
15). Regarding function, we and others reported for example 
significantly reduced adipogenic differentiation capacity of UCB-
MSC (16). Regarding the stromal supportive capacity, a recent 
study indicates that only BM-MSC (not MSC from white adipose 
tissue, umbilical cord, and skin) are capable to form a functional 
hematopoietic niche (17).
Immunomodulatory functions have been reported for all 
types of MSC tested. Strikingly, analyses directly comparing these 
populations with their immunomodulatory effects are limited. As 
many scientific groups just use one single source for MSCs in 
their experiments –  indeed beneficial for the reproducibility of 
their own data – it renders it hard to compare the results to those 
of other scientists and to draw conclusions about their clinical 
efficacy. To assess immunomodulation, most groups utilize a 
mixed lymphocyte reaction (MLR) assay or an assay measuring 
T cell proliferation induced by mitogens or CD3/CD28 stimula-
tion. Fewer groups address distinct effects on T cell subsets (Th1, 
Th2, Th17, and regulatory T cells) and antigen-presenting cells 
(APCs) [reviewed in Ref. (2, 18, 19)]. Although the vast major-
ity of studies confirm MSCs to inhibit the immune response, 
recent data identified allogeneic MSCs to be immunogenic and 
immune-rejected under appropriate conditions (20–22). There is 
a large diversity in soluble factors to mediate the effects of MSCs, 
thus it remains to be clarified whether MSC origin and culture 
conditions use different molecular mechanisms to exert their 
effects (2, 23). Some interesting data suggest intrinsic differences 
in expression of immune-related signature genes, mi- and tRNA 
species (24, 25). However, a summary of these is beyond the scope 
of this review. Here, we focused on studies, which directly com-
pared two or more MSC tissue sources addressing MSC effects on 
T cell subpopulations or APCs, such as monocytes, macrophages, 
or dendritic cells (DCs) (summarized in Table 1).
eFFeCTS On T CeLLS
effects on naïve CD4+ T Cells
The exerted effects on naïve CD4+ T cells are of a suppressing and 
polarizing nature, meaning MSCs inhibit the proliferation and 
activation of naïve CD4+ T helper cells (Th cells). They are able to 
influence the differentiation of Th0 cells into Th1, Th2, Th17, or 
regulatory T cells (Tregs) (36, 41, 42). MSCs seem to hamper T 
cell proliferation by arresting T cells in the G0/G1 phase of the cell 
cycle (12, 43), thus reducing the total number of T cells undergo-
ing activation. MSCs exert their immunomodulatory functions 
through numerous molecules. Although trans-well experiments 
show an inhibiting function of MSCs, most studies confirm a 
TABLe 1 | Studies directly comparing different sources of MSCs, reporting differences in immunomodulatory capacities.
Reference Populations compared Parameters Outcome
Bárcia et al. (26) BM, UC Immunomoda UC > BM
Immunogenicity UC < BM
Barlow et al. (9) BM, PL Proliferation PL > BM
Immunogenicity BM = PL
Castro-Manrreza et al. (27) BM, UCB, PL Immunomodb BM = UCB > PL
Hass et al. (7) BM, AT, UC Proliferation UC > AT > BM
Senescence UC < AT < BM
Ivanova-Todorova et al. (28) BM, AT Immunomodc AT > BM
Jin et al. (29) BM, AT, UCB Proliferation UCB > AT = BM
Immunomodd UCB > AT = BM
Senescence UCB < AT = BM
Kern et al. (5) BM, AT, UCB Proliferation UCB > AT > BM
Isolation success rate BM = AT > UCB
Colony frequency AT > BM > UCB 
Li et al. (30) BM, AT, UC, PL Proliferation WJ > AT > PL > BM
Immunomode WJ > PL > AT > BM
Luan et al. (31) BM, PL Immunomodf BM = PL
Montespan et al. (32) BM, AT Immunomodg AT > BM
Najar et al. (33, 34) BM, AT, UC Immunomodh AT > BM = UC
Prasanna et al. (22) BM, WJ Immunogenicity BM = WJ
Immunomodi WJ ≠ BM
Puissant et al. (35) BM, AT Immunogenicity BM = AT
Immunomodj BM = AT
Ribeiro et al. (36) BM, AT, UC, T/NK cell inhibition AT > BM = UC
B cell inhibition BM = AT (UC none)
Roemeling-van Rhijn et al. (37, 38) BM, AT Immunomodk BM = AT
Immunomodl AT < BM
Stubbendorf et al. (39) UCB, WJ, PL, UCL Proliferation UCL > UCB > WJ = PL
Immunomodm UCL > UCB = WJ = PL
Immunogenicity UCL ≤ PL ≤ WJ = UCB
Xishan et al. (12) BM, AT Proliferation AT > BM
Immunomodn BM > AT
Yoo et al. (40) BM, AT, UCB, WJ Immunomodf BM = AT = UCB = WJ
Cytokineso Only UCB and WJ
aMSCs + PBMCs/T cells. MLR assay to assess lymphocyte proliferation and immunogenicity. Flow cytometry to measure Treg induction. Comparative gene expression analysis.
bMSCs + T cells (±transwell). Proliferation assay for CD4+ and CD8+ T cells. Flow cytometry to assess T cell activation and CTLA-4 and PD-L1 expression. Multiplex assay to 
measure IFN-γ, TNF-α, IL-10, and IL-4.
cMSCs + Monocytes. Flow cytometry to assess CD14, CD80, CD83, CD86, and HLA-DR. ELISA to measure IL-10 and IL-18. Proteome profile assay for 36 cytokines (e.g., CCL-3 
and CCL-4).
dMSCs + LPS stimulated rat macrophages. ELISA to assess IL-1α, IL-6, and IL-8 and Ang-1.
eMSCs + T cells. T cell proliferation was assessed.
fMSCs + T cells. T cell proliferation assay. ELISA to assess IFN-γ and IL-10, or TNF-α.
gMSCs + PBMCs. Flow cytometry analysis for HLA-G. MLR assay to assess immunosuppression.
hMSCs + mitogenic/allogenic stimulated T cells. T cell activation and proliferation assays. Subset analysis for CD4+ and CD8+ T cells. PCR for COX1 and COX2. ELISA for PGE2 
MSCs + T cells. MSCs were primed with IFN-α, IFN-γ, TNF-α, or IL-1β or unstimulated. T cell proliferation assay. Flow cytometry to assess lymphocyte activation. ELISA for IFN-γ, 
IL-8, and CCL5. T cell migration assay.
iMSC + PBMCs stimulated with PHA or MLR; MSC primed with IFN-γ or TNF-α: immunogenicity and T cell proliferation; PBMC cytokine profiles, activation markers, and immune-
suppressive factors (IDO, PGE2, HGF, CIITA).
jMSCs + PBMCs: MLR or mitogen-induced T cell proliferation, time- and dose-dependent suppression, dependent on soluble mediators (but most probably not TGF-β, HGF, and 
IL-10).
kMSCs + PBMCs: PBMC proliferation assay. PCR for IDO, TGF-β, and CXCL-10. Application of PBMCs and MSCs in an in vivo mouse allograft rejection model.
lMSCs and CD8+ T cells: induction of HLA-specific alloreactivity by MSC-educated CD8+ TC.
mMSCs stimulated with IFN-γ and MSCs + T cells. ELISA for IL-2, IL-10, and TGF-β1. Electrophoresis for IDO.
nMSCs + PHA stimulated T cells. Effects on T cell proliferation, MLR assay, T cell cycle, T cell apoptosis, early activation, and T cell subsets were assessed.
oMSC + PHA-stimulated T cells: cytokines: IL-12, IL-15, and PDGF-AA.
AT, adipose tissue; BM, bone marrow; MLR, mixed lymphocyte reaction; MSC, mesenchymal stromal cells; PBMC, peripheral blood mononuclear cells; PL, placenta;  
Treg, regulatory T cells; CTL, cytotoxic T lymphocytes; DC, dendritic cells UC, umbilical cord; UCB, umbilical cord blood; WJ, Wharton’s jelly.
more pronounced effect without trans-wells, highlighting the 
importance of cell-cell contact in mediating immunomodulatory 
functions. Prostaglandin E2 (PGE2) seems to play an important 
role in suppressing the immune response (33). Just recently, 
evidence arose that MSC-derived microvesicles contain a variety 
of immunomodulatory factors, including miRNA and tRNA 
species (25, 44). Di Nicola et al. proposed transforming growth 
factor (TGF)-β and hepatocyte growth factor (HGF) as important 
mediators, as blockage of both significantly reduced the suppres-
sive effect of MSCs (45). Another group identified indoleamine 
2,3-dioxygenase (IDO) to be involved (46). IDO catalyzes the 
conversion of tryptophan, an essential molecule in the activation 
of T cells, to kynurenine and has been identified as a key pathway 
for inhibiting T cell response. Additionally, Human Leukocyte 
Antigen-G5 (HLA-G5) was found to be required to suppress T 
cell function and to induce Tregs (32, 47).
Comparison
Comparative studies have produced conflicting results. Puissant 
et al. report similar inhibition of T cell proliferation, both induced 
in MLR or mitogens, in presence of BM- or AT-MSCs (35). In 
both settings suppression was induced by soluble mediators. In 
contrast, whereas Ribeiro et al. (36) found AT-MSCs (compared 
to BM-MSCs and UC-MSCs) to have the strongest suppressive 
effect on the activation and acquisition of lymphoblast char-
acteristics on T cells, Xishan et  al. (12) determined BM-MSCs 
to have a superior immunosuppressive effect over AT-MSCs. 
In a study comparing MSCs from bone marrow, adipose tissue 
and Wharton’s jelly, AT-MSCs showed the strongest effect on 
downregulating the activation marker CD38 on T cells, followed 
by UC-MSCs, whereas BM-MSCs had the weakest effect (33). 
The authors showed AT-MSCs to be the most potent popula-
tion in inhibiting allogeneic-induced T cell proliferation (33). 
Interestingly, different levels of the enzyme cyclooxygenase-1 
(COX1), which is essential in PGE2 production, were observed, 
with highest levels of COX1 in AT-MSC (33). Conflicting data, 
however, was presented by Li et al., who determined MSCs from 
Wharton’s jelly to possess the strongest inhibitory effect on T cell 
proliferation compared to AT-MSCs, BM-MSCs, and PL-MSCs 
(30). Similar inhibitory effects on T cell proliferation, activation, 
and cytokine secretion are reported by Luan et  al. comparing 
PL- and BM-MSC (31). They identified programed death-ligand 
1 (PD-L1, CD274, or B7-H1) and B7H4 as negative regulators.
effects on CD4+ Th1 Cells
A large number of studies have been performed to explore the 
effects of MSCs on Th1 cells, considered to be the main effector 
cells of proinflammatory cell-mediated immunity and organ-
specific autoimmune disorders (23, 48, 49). The results obtained 
from these studies usually imply an inhibiting effect on Th1 cells 
(12, 41, 48–50). However, there are conditions in which MSCs 
seem to promote Th1 cells and inhibit the differentiation of Th2 
cells (49). Cho et al. described AT-MSCs to reduce Th2-associated 
cytokines (interleukin IL-4, IL-5) and increase Th1-derived 
interferon (IFN)-γ and IL-2 in a model of eosinophilic nasal 
polyps (51). These data are corroborated by other studies, con-
firming the Th2-inhibiting function of MSCs in Th2-dominated 
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ity of studies confirm MSCs to inhibit the immune response, 
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regulatory T cells (Tregs) (36, 41, 42). MSCs seem to hamper T 
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Immunogenicity BM = PL
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Hass et al. (7) BM, AT, UC Proliferation UC > AT > BM
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Luan et al. (31) BM, PL Immunomodf BM = PL
Montespan et al. (32) BM, AT Immunomodg AT > BM
Najar et al. (33, 34) BM, AT, UC Immunomodh AT > BM = UC
Prasanna et al. (22) BM, WJ Immunogenicity BM = WJ
Immunomodi WJ ≠ BM
Puissant et al. (35) BM, AT Immunogenicity BM = AT
Immunomodj BM = AT
Ribeiro et al. (36) BM, AT, UC, T/NK cell inhibition AT > BM = UC
B cell inhibition BM = AT (UC none)
Roemeling-van Rhijn et al. (37, 38) BM, AT Immunomodk BM = AT
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Immunomodm UCL > UCB = WJ = PL
Immunogenicity UCL ≤ PL ≤ WJ = UCB
Xishan et al. (12) BM, AT Proliferation AT > BM
Immunomodn BM > AT
Yoo et al. (40) BM, AT, UCB, WJ Immunomodf BM = AT = UCB = WJ
Cytokineso Only UCB and WJ
aMSCs + PBMCs/T cells. MLR assay to assess lymphocyte proliferation and immunogenicity. Flow cytometry to measure Treg induction. Comparative gene expression analysis.
bMSCs + T cells (±transwell). Proliferation assay for CD4+ and CD8+ T cells. Flow cytometry to assess T cell activation and CTLA-4 and PD-L1 expression. Multiplex assay to 
measure IFN-γ, TNF-α, IL-10, and IL-4.
cMSCs + Monocytes. Flow cytometry to assess CD14, CD80, CD83, CD86, and HLA-DR. ELISA to measure IL-10 and IL-18. Proteome profile assay for 36 cytokines (e.g., CCL-3 
and CCL-4).
dMSCs + LPS stimulated rat macrophages. ELISA to assess IL-1α, IL-6, and IL-8 and Ang-1.
eMSCs + T cells. T cell proliferation was assessed.
fMSCs + T cells. T cell proliferation assay. ELISA to assess IFN-γ and IL-10, or TNF-α.
gMSCs + PBMCs. Flow cytometry analysis for HLA-G. MLR assay to assess immunosuppression.
hMSCs + mitogenic/allogenic stimulated T cells. T cell activation and proliferation assays. Subset analysis for CD4+ and CD8+ T cells. PCR for COX1 and COX2. ELISA for PGE2 
MSCs + T cells. MSCs were primed with IFN-α, IFN-γ, TNF-α, or IL-1β or unstimulated. T cell proliferation assay. Flow cytometry to assess lymphocyte activation. ELISA for IFN-γ, 
IL-8, and CCL5. T cell migration assay.
iMSC + PBMCs stimulated with PHA or MLR; MSC primed with IFN-γ or TNF-α: immunogenicity and T cell proliferation; PBMC cytokine profiles, activation markers, and immune-
suppressive factors (IDO, PGE2, HGF, CIITA).
jMSCs + PBMCs: MLR or mitogen-induced T cell proliferation, time- and dose-dependent suppression, dependent on soluble mediators (but most probably not TGF-β, HGF, and 
IL-10).
kMSCs + PBMCs: PBMC proliferation assay. PCR for IDO, TGF-β, and CXCL-10. Application of PBMCs and MSCs in an in vivo mouse allograft rejection model.
lMSCs and CD8+ T cells: induction of HLA-specific alloreactivity by MSC-educated CD8+ TC.
mMSCs stimulated with IFN-γ and MSCs + T cells. ELISA for IL-2, IL-10, and TGF-β1. Electrophoresis for IDO.
nMSCs + PHA stimulated T cells. Effects on T cell proliferation, MLR assay, T cell cycle, T cell apoptosis, early activation, and T cell subsets were assessed.
oMSC + PHA-stimulated T cells: cytokines: IL-12, IL-15, and PDGF-AA.
AT, adipose tissue; BM, bone marrow; MLR, mixed lymphocyte reaction; MSC, mesenchymal stromal cells; PBMC, peripheral blood mononuclear cells; PL, placenta;  
Treg, regulatory T cells; CTL, cytotoxic T lymphocytes; DC, dendritic cells UC, umbilical cord; UCB, umbilical cord blood; WJ, Wharton’s jelly.
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inflammatory conditions, such as allergic airway inflammation 
(52). In an inflammatory environment, high levels of IFN-γ and/
or tumor necrosis factor (TNF)-α increase the expression of TGF-
β by MSCs (53, 54), which in turn prompts Th1 cells to express 
immunosuppressive IL-10 and ultimately reduces their IFN-γ 
production. Furthermore, MSC mediate a downregulation of 
the Th1 cells IFN-γ receptor, which renders them less susceptible 
to IFN-γ (55). In a recent study, MSCs-induced and expanded a 
subpopulation of T-bet+ Th1 cells co-expressing IFN-γ and IL-10 
(55). T-bet is a Th1 cell-specific transcription factor (56). This sug-
gests that the influence of MSCs on IFN-γ expression is dependent 
on several factors, such as the cytokine milieu, the stimulation 
methods or the types of cells present, showing that we are far from 
having a full grasp of the effects of MSCs on immune cells.
Comparison
AT-MSCs and BM-MSCs showed similar results in inhibiting Th1 
differentiation, as both significantly reduced the levels of IL-2 and 
IFN-γ (12). Another study compared several MSC populations 
from birth-associated tissue (umbilical cord lining, cord blood, 
placenta, and Wharton’s jelly), resulting in cord lining MSCs to 
emerge as the most potent in dampening Th1 and Th2 responses 
and reducing release of IFN-γ by lymphocytes (39). Castro-
Manrreza et al. compared BM-MSCs, UC-MSCs, and PL-MSCs 
and identified similar proliferation suppression capacities for 
BM-MSCs and UC-MSCs, but PL-MSCs showed significantly 
weaker CD4+/CD8+ T lymphocyte suppression (27). AT-MSCs 
exerted the strongest inhibition on IFN-γ secretion and T cell 
proliferation compared to BM-MSCs and WJ-MSCs (34).
effects on CD4+ Th2 Cells
Th2 cells have several functions in the humoral-mediated immune 
response, as they host the defense against extracellular parasites, 
inhibit Th1 cells and DCs via IL-10, stimulate B cells via IL-4 
and can induce isotype-switches in B cells (57). MSCs have been 
shown to enhance anti-inflammatory IL-4 production by Th2 cells, 
supposedly via a PGE2 (48). In inflammatory diseases that are 
associated with high amounts of Th2 cells (e.g., allergies, asthma, 
Crohn’s disease), MSCs were able to ameliorate disease activity by 
inhibiting the cytokine production of Th2 cells (IL-4 and IL-5) and 
increase Th1-derived cytokines (IFN-γ and IL-2) (51, 58).
Comparison
There are a small number of studies concentrating on the com-
parison of various MSC sources on T cell subsets. Xishan et al. 
compared AT-MSCs and BM-MSCs on their ability to induce Th0 
differentiation into Th1 and Th2 cells and could show that both 
populations had no significant effect on the levels of the Th2-
associated cytokines IL-4 and IL-10 (12). Concerning Th2 cells, 
data is especially scarce.
effects on CD4+ Th17 Cells
Th17 cells play an important role in the human immune system 
as effectors against extracellular bacterial and fungal infections, 
but have also been associated with autoimmune diseases, such as 
multiple sclerosis, psoriasis, rheumatoid arthritis, inflammatory 
bowel disease, systemic lupus erythematosus, and asthma (59). 
Although studies about the effects of MSCs on Th17 cells seem 
to yield rather consistent results, presenting MSCs as potent 
inhibitors of Th17-mediated immune responses (60–62), data 
exists where Th17 cells appear to be stimulated by MSCs in vitro 
(63). The time at which MSCs are added could be important, as 
Carrión et al. demonstrated opposing effects of MSCs on Th1 and 
Th17 cells relative to the state of CD4+ T cell activation (49).
Comparison
AT-MSCs, UC-MSCs, and BM-MSCs have all proven to be effec-
tive in suppressing the Th17 immune response (41, 60, 64), but 
studies directly comparing them are rare. In a mouse model of 
experimental colitis, UC-MSCs and BM-MSCs demonstrated 
a similar inhibition of Th17 cells, shifting the Th17/Treg ratio 
toward a more immunosuppressive balance (64).
effects on CD4+ FoxP3+ Regulatory T 
Cells (Tregs)
Regulatory T cells are either derived in the thymus as mature 
Tregs, or from CD4+CD25− naïve T cells as peripherally derived 
Tregs under the influence of TGF-β and IL-2 (65). Tregs target 
effector T cells and DCs (65, 66) by inhibiting their differen-
tiation, function, and maturation to prevent autoimmunity and 
establish a peripheral tolerance (67). MSCs have been shown to 
induce Tregs via a multitude of factors. HLA-G5, a non-classical 
HLA class I molecule, plays an important role in the induction 
of Tregs (68). Another factor of MSCs involved in the activation 
of Tregs is TGF-β, which seems to be constitutively expressed by 
MSCs (69). Additionally, MSCs were reported to elevate IL-10 
production by Tregs and DCs (70, 71), whereby DC-derived 
IL-10 in turn promotes the expansion of Tregs (72). Tregs can 
also be indirectly activated by MSCs through an upregulation 
of Fas ligand (FasL)/Fas-mediated death pathway, which targets 
T cells via cell-cell contact and leads to increased apoptosis and 
Treg induction (73). In several in vivo settings, MSCs increased 
Tregs, thereby ameliorating disease states as well as promoting 
graft survival in transplant experiments (41, 50, 74–76).
Comparison
In an in vitro study that compared BM-MSCs and UC-MSCs on 
their ability to induce Tregs, UC-MSCs had a significantly greater 
potential to induce Tregs than BM-MSCs (26). Chao et  al., on 
the other hand, did not report a difference in Treg induction of 
BM-MSCs and UC-MSCs in an in vivo experiment (77).
effects on CD8+ T Cells (CTL)
Cytotoxic T lymphocytes (CTLs) are major effectors in the immune 
system through targeting virus-infected cells as well as tumor 
cells. CTLs have a crucial role in autoimmunity and transplant 
rejection. CTL activation is triggered following the interaction 
of the T cell receptor (TCR) with the specific allogeneic peptide–
HLA-I complex. The activation of lymphocytes can be divided 
into several steps, which all have a corresponding phenotype: 
CD69−CD25−HLA-DR− (non-activated), CD69+CD25−HLA-DR− 
(earlier activated), CD69+CD25+HLA-DR− (intermediate 
activated) and CD69+CD25+HLA-DR+ (later activated). It was 
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reported that MSCs are able to dampen the immune response 
of CTLs as well as inhibiting their proliferation and maturation 
(36, 37, 51). MSC downregulate the CD8 surface marker on CTLs 
via an indirect pathway involving CD14+ monocytes, requiring 
cell-cell contact between the monocytes and the CTLs (78). In 
this process, CD28 is downregulated on CTLs indicating loss of 
effector-type and gain of regulatory functions (78).
Comparison
Ribeiro et al. investigated AT-MSCs, BM-MSCs, and UC-MSCs 
as to their effect of inhibiting CD4+/CD8+ lymphocyte activation 
(36). Co-culture with BM-MSCs and UC-MSCs similarly inhib-
ited lymphocyte activation, whereas the majority of the CD8+ cells 
were of the earlier activated phenotype. AT-MSCs here emerged 
as the most immunosuppressive population, as the majority of the 
T Cells were found to be in the non-activated compartment (36). 
Different effects on CD8+ mediated alloreactivity are reported by 
Roemeling-van Rhijn et al., addressing the capacity of AT- versus 
BM-MSC to induce HLA-specific alloreactivity (38). CD8+ T cells 
educated with IFN-γ-treated AT-MSC evoked 31% specific lysis of 
AT-MSCs with identical HLA. IFN-γ-treated BM-MSC, however, 
resulted in 76% HLA-specific killing of HLA-identical BM-MSC.
eFFeCTS On MOnOCYTeS, 
MACROPHAGeS, AnD DenDRiTiC CeLLS
Monocytes are a subpopulation of leukocytes able to differentiate 
into macrophages and DCs. Macrophages and DCs are antigen-
presenting cells that can initiate an immune response and act as 
a mediator between the innate and the adaptive immune system. 
MSCs were reported to strongly induce the secretion of IL-10 on 
CD14+ monocytes via HGF, thereby suppressing T cell prolifera-
tion (79). Melief et al. could show that MSCs promote the survival 
of monocytes and induce the differentiation into CD163+ CD206+ 
type 2 macrophages, which secrete IL-10 and CCL18 (69). CCL18 
in turn has a crucial role in inducing Tregs (69). MSCs were 
frequently shown to be able to inhibit the proinflammatory func-
tions of DCs and macrophages and skew the cells toward a more 
immunosuppressive response (70, 71, 80). The proinflammatory 
molecules TNF-α and macrophage inflammatory protein (MIP)-
1β, produced by macrophages and mature DCs, were suppressed 
under the influence of MSCs (80). Concerning maturation mark-
ers such as CD1a, CD14, CD83 and HLA-DR, MSCs inhibited 
the maturation of DCs and furthermore downregulated the 
costimulatory molecules CD86/CD80 (81, 82). Conflicting data 
exist, as Laranjera et al. could not detect any influence of MSCs 
on maturation markers CD83, CCR7, and HLA-DR (80) on 
DCs, thus leading the group to suppose that MSCs exhibit their 
anti-inflammatory functions on macrophages and DCs mainly by 
inhibiting the secretion of proinflammatory cytokines. MSCs are 
also able to inhibit the differentiation at a more upstream step by 
interfering with monocyte maturation (83).
Comparison
AT-MSCs seem to have a more pronounced effect on DC differ-
entiation than BM-MSCs (28). Saeidi et al. examined UC-MSCs 
on their potential to interfere with maturation and endocytotic 
capability of DCs comparing them with BM-MSCs (81). While 
being equally effective in hampering the maturation of DCs, 
UC-MSCs had a stronger effect on reducing the endocytotic abil-
ity of DCs (81). Jin et al. compared anti-inflammatory activity of 
BM-, AT-, and UCB-MSCs (29). UCB-MSCs were most potent 
in suppressing cytokine release from LPS-challenged alveolar 
macrophages. Angiopoietin-1 was at least partly responsible for 
this effect.
COnCLUSiOn
The increasing numbers of studies conducted on compar-
ing MSC sources in  vitro and in  vivo yield largely congruent 
results, presenting MSCs as promising cells for a multitude 
of immunological applications (Table  1). Nevertheless, the 
heterogeneity in MSC populations and experimental protocols 
still poses a major obstacle when trying to compare and merge 
different results and to translate them into clinical practice (84). 
Our survey reflects that the vast majority of data showed no 
significant deficiencies in the immunomodulatory potential of 
MSCs from alternative sources but often even stronger immu-
nosuppressive capabilities than BM-MSCs (26, 28, 30, 33, 34, 
36, 81). This was especially the case for MSCs from adipose 
tissue (28, 32–34, 36). This claim, however, is based on the few 
studies directly comparing MSCs from different tissue sources. 
Future studies should elucidate whether the similarities of tissue 
MSCs in vitro relate to similar functions in situ or are artificially 
gained by ex vivo isolation and culture adaptation (85, 86) and 
whether the subtle differences in function relate to the role of 
MSCs in situ. What is certain is that MSCs expanded in vitro 
are highly sensitive to their microenvironment; they may 
alternate their function based on the surrounding conditions. 
Important parameters are the culture conditions (e.g., choice of 
serum supplement), types of immune cells present, cell activa-
tion status, ratio of MSC to immune cells and, of course, the 
cytokine levels in the milieu (87–90). Additionally, variations 
in isolation methods, culture media, cell counts, and different 
stimulation protocols can further blur the potential differences 
among distinct MSC sources. A standardization of assays to 
assess the effects of MSCs is essential to guarantee trustworthy 
and reproducible results (18). Ideally, these assays are capable 
of predicting efficacy of MSCs in  vivo, to serve as potency 
assay. We would therefore appreciate more comparative studies 
to give us a better understanding of the immunomodulatory 
mechanisms of MSCs, facilitating the choice between differ-
ent sources for defined clinical settings to improve safety and 
efficacy of MSC-based therapies.
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